Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer

Simple item page
dc.contributor.authorMah, C.Y.
dc.contributor.authorNguyen, A.D.T.
dc.contributor.authorNiijima, T.
dc.contributor.authorHelm, M.
dc.contributor.authorDehairs, J.
dc.contributor.authorRyan, F.J.
dc.contributor.authorRyan, N.
dc.contributor.authorQuek, L.-E.
dc.contributor.authorHoy, A.J.
dc.contributor.authorDon, A.S.
dc.contributor.authorMills, I.G.
dc.contributor.authorSwinnen, J.V.
dc.contributor.authorLynn, D.J.
dc.contributor.authorNassar, Z.D.
dc.contributor.authorButler, L.M.
dc.date.issued2024
dc.descriptionPublished online: 12 January 2024
dc.description.abstractBACKGROUND: Peroxisomes are central metabolic organelles that have key roles in fatty acid homoeostasis. As prostate cancer (PCa) is particularly reliant on fatty acid metabolism, we explored the contribution of peroxisomal β-oxidation (perFAO) to PCa viability and therapy response. METHODS: Bioinformatic analysis was performed on clinical transcriptomic datasets to identify the perFAO enzyme, 2,4-dienoyl CoA reductase 2 (DECR2) as a target gene of interest. Impact of DECR2 and perFAO inhibition via thioridazine was examined in vitro, in vivo, and in clinical prostate tumours cultured ex vivo. Transcriptomic and lipidomic profiling was used to determine the functional consequences of DECR2 inhibition in PCa. RESULTS: DECR2 is upregulated in clinical PCa, most notably in metastatic castrate-resistant PCa (CRPC). Depletion of DECR2 significantly suppressed proliferation, migration, and 3D growth of a range of CRPC and therapy-resistant PCa cell lines, and inhibited LNCaP tumour growth and proliferation in vivo. DECR2 influences cell cycle progression and lipid metabolism to support tumour cell proliferation. Further, co-targeting of perFAO and standard-of-care androgen receptor inhibition enhanced suppression of PCa cell proliferation. CONCLUSION: Our findings support a focus on perFAO, specifically DECR2, as a promising therapeutic target for CRPC and as a novel strategy to overcome lethal treatment resistance.
dc.description.statementofresponsibilityChui Yan Mah, An Dieu Trang Nguyen, Takuto Niijima, Madison Helm, Jonas Dehairs, Feargal J. Ryan, Natalie Ryan, Lake-Ee Quek, Andrew J. Hoy, Anthony S. Don, Ian G. Mills, Johannes V. Swinnen, David J. Lynn, Zeyad D. Nassar, and Lisa M. Butler
dc.identifier.citationBritish Journal of Cancer, 2024; 130(5):741-754
dc.identifier.doi10.1038/s41416-023-02557-8
dc.identifier.issn0007-0920
dc.identifier.issn1532-1827
dc.identifier.orcidMah, C.Y. [0000-0002-8820-4037]
dc.identifier.orcidNguyen, A.D.T. [0000-0001-7415-7754]
dc.identifier.orcidNassar, Z.D. [0000-0002-7779-2697]
dc.identifier.orcidButler, L.M. [0000-0003-2698-3220]
dc.identifier.urihttps://hdl.handle.net/2440/142700
dc.language.isoen
dc.publisherSpringer Nature
dc.rights© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creativecommons.org/licenses/by/4.0/.
dc.source.urihttp://dx.doi.org/10.1038/s41416-023-02557-8
dc.subjectPeroxisomal β-oxidation
dc.subject.meshCell Line, Tumor
dc.subject.meshHumans
dc.subject.meshFatty Acids
dc.subject.meshReceptors, Androgen
dc.subject.meshAndrogens
dc.subject.meshCell Proliferation
dc.subject.meshMale
dc.subject.meshLipid Metabolism
dc.subject.meshProstatic Neoplasms, Castration-Resistant
dc.titlePeroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer
dc.title.alternativePeroxisomal beta-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer
dc.typeJournal article
pubs.publication-statusPublished

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl_142700.pdf
Size:
3.1 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Research Outputs